고서머 바이오(GOSS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.15 (-9.45%), 시가총액 $0.08B, 52주 범위 $0.32 ~ $3.79.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and i
고서머 바이오의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
고서머 바이오의 현재 주가는 $0.15 (-9.45%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
고서머 바이오의 시가총액은 약 $0.08B입니다.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in